Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152450 | 0.83 | TDP1 (0.36) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL27680256 | 0.81 | TDP1 (0.35) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL14276786 | 0.79 | TDP1 (0.39) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2542864 | 0.79 | KDM4C (0.36) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2537978 | 0.79 | KDM4C (0.36) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2541061 | 0.78 | DGAT1 (0.45) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2543922 | 0.78 | DGAT1 (0.45) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL76832 | 0.77 | KDM4C (0.41) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL14152176 | 0.76 | CA1 (0.39) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL31604952 | 0.76 | TDP1 (0.40) | TDP1DGAT1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| EP-1483228-B1 | NK1 ANTAGONISTS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| WO-2009098901-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | WO | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080058391-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058391-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2008017691-A1 | PYRIDINE DERIVATIVES AS SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058391-A1 | NOVEL COMPOUNDS | HCN3, KCNN3, HCN4 | TDP1 3849/4885DGAT1 3693/4885CA1 1247/4885 |
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | TDP1 659/4885DGAT1 4832/4885CA1 4823/4885 |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | TDP1 1011/4885DGAT1 3279/4885CA1 2790/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | TDP1 1011/4885DGAT1 3279/4885CA1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.